Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 101–200 of 1,139
The Kidney in Obesity: Current Evidence, Perspectives and Controversies
Kounatidis, D. C., Vallianou, N. G., Stratigou, T., Voukali, M., Karampela, Ι., & Dalamaga, Μ. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00583-y · Cited by 56
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
NK2R control of energy expenditure and feeding to treat metabolic diseases
Sass, F., Ma, T., Ekberg, J. H., Kirigiti, M. A., García‐Ureña, M., Dollet, L., Brown, J. M., Basse, A. L., Yacawych, W. T., Burm, H. B., et al. (2024) · Nature · doi:10.1038/s41586-024-08207-0 · Cited by 53
Müllertz, A. L. O., Sandsdal, R. M., Jensen, S. B. K., & Torekov, S. S. (2024) · Obesity Reviews · doi:10.1111/obr.13717 · Cited by 46
“69 Oral semaglutide has been found effective for treating type 2 diabetes, 70,71 and now also for obesity.”
BackgroundGasiorek, A., Heydorn, A., Gabery, S., Hjerpsted, J. B., Kirkeby, K., Kruse, T., Petersen, S. B., Toubro, S., Vegge, A., & Key, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01176-6 · Cited by 46
Bone health in adults with obesity before and after interventions to promote weight loss
Paccou, J., & Compston, J. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00163-3 · Cited by 54
Jakubowska, A., Roux, C. W. L., & Viljoen, A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1942 · Cited by 45
“Although, most participants lost weight, there was heterogenicity, that has been well-documented in obesity studies [66] and those with higher BMI above 35 experienced greater mean percentage weight loss [64].”
BackgroundInfluentialCarbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Mohaghegh, N., Ahari, A. F., Buttles, C., Davani, S., Hoang, H., Huang, Q., Huang, Y., Hosseinpour, B., Abbasgholizadeh, R., Cottingham, A. L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c10742 · Cited by 51
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Dietary and metabolic effects on intestinal stem cells in health and disease
Shay, J. E. S., & Yilmaz, Ö. H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00980-7 · Cited by 64
“Global obesity rates have rapidly increased; however, innovative pharmacological therapies are on the horizon, with advances in novel, highly effective gut-derived incretin therapies and other therapeutic targets 228–231 .”
Obesity: The Perfect Storm for Heart Failure
Lembo, M., Strisciuglio, T., Fonderico, C., Mancusi, C., Izzo, R., Trimarco, V., Bellis, A., Barbato, E., Esposito, G., Morisco, C., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14641 · Cited by 56
“167 Notably, recent evidence from the SE-LECT trial has demonstrated the important protective effect of semaglutide in terms of CV morbidity and mortality in overweight/obese patients.”
BackgroundO'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 48
Psaltis, J. P., Marathe, J., Nguyen, M. T., Le, R., Bursill, C. A., Marathe, C. S., Nelson, A. J., & Psaltis, P. J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22070 · Cited by 51
COHEN, R. V., Park, J. Y., Prager, G., Bueter, M., le Roux, C. W., Parmar, C. D., Kermansaravi, M., Salminen, P. T. P., & Miras, A. D. (2024) · British journal of surgery · doi:10.1093/bjs/znae284 · Cited by 50
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
“113,114 In summary, to date, the evidence is limited as to the most efficacious”
BackgroundStructural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 52
Camilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
The effects of GLP‐1RA on inflammatory skin diseases: A comprehensive review
Paschou, I. A., Sali, E., Paschou, S. Α., Ψαλτοπούλου, Θ., Nicolaidou, E., & Stratigos, A. J. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.20694 · Cited by 56
Hinds, C. E., Peace, E., Chen, S., Davies, I., Eid, L. E., Tomás, A., Tan, T., MINNION, J. S., Jones, B. J., & Bloom, S. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15288 · Cited by 42
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Self-citationLupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 40
“23 Its novelty arises from its additional agonism to the glucagon re - ceptor that is known to increase hepatic glucose, and thought to increase efficacy by reducing energy intake and enhancing energy expenditure.”
BackgroundMadsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“Overall, 338 adults with a mean BMI of 37.3 kg/m2 (107.7 kg) were enrolled [123].”
InfluentialGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“…multi-agonists, such as tirzepatide (co-agonist of GLP-1R and glucose-dependent in-sulinotropic polypeptide receptor [GIPR]), and retatrutide (tri-agonist of GLP-1R, GIPR, and glucagon receptor), are achieving unprecedented placebo-subtracted weight loss of ≥ 20% in clinical trials (80, 81).”
Glucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
Alsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 39
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
“This is especially important as the average weight-loss effect continues to increase among emerging GLP1Ra-based treatments [42, 43].”
Ayesh, H., Nasser, S. A., Ferdinand, K. C., & Leon, B. G. C. (2025) · Circulation Research · doi:10.1161/circresaha.124.325535 · Cited by 45
New Molecules and Indications for GLP-1 Medicines
Gonzalez-Rellan, M. J., & Drucker, D. J. (2025) · JAMA · doi:10.1001/jama.2025.14392 · Cited by 50
Obesity and Weight Loss Strategies for Patients With Heart Failure
Vest, A. R., Schauer, P. R., Rodgers, J. E., Sanderson, E., LaChute, C., Seltz, J., Lavie, C. J., Mandras, S. A., Tang, W. H. W., & daSilva‐deAbreu, A. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.06.006 · Cited by 47
Gut hormones and appetite regulation
Hong, S.-H., & Choi, K. M. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000859 · Cited by 35
“…have been reported (Table 1). least one weight-related disease, 12 mg administration of retatrutide reduced the mean weight by 24.2% after 48 weeks [45 && ] Moreover, in the reta-trutide group, improvements in waist circumference, systolic and diastolic blood pressure, and glycated hemoglobin,…”
BackgroundInfluentialDutta, D., Nagendra, L., Anne, B., Kumar, M., Sharma, M., & Kamrul‐Hasan, A. B. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.743 · Cited by 35
Myasoedova, V. A., Bozzi, M., Valerio, V., Moschetta, D., Massaiu, I., Rusconi, V., Di Napoli, D., Ciccarelli, M., Parisi, V., Agostoni, P., et al. (2023) · Antioxidants · doi:10.3390/antiox13010016 · Cited by 35
“Subsequently, retatrutide entered a phase 2 clinical trial, aiming to develop it for the treatment of T2DM, obesity, and related comorbidities [101,103].”
InfluentialWestermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
Kreiner, F. F., Schytz, P. A., Heerspink, H. J. L., von Scholten, B. J., & Idorn, T. (2023) · Biomedicines · doi:10.3390/biomedicines11092498 · Cited by 52
“Furthermore, retatrutide, a GLP-1/GIP/glucagon triagonist, is also in development for glycaemic control and weight management, and has shown marked weight-lowering effects in relatively short-term studies [135].”
BackgroundPetersen, K. F., Dufour, S., Mehal, W. Z., & Shulman, G. I. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.023 · Cited by 46
Giblin, K., Kaplan, L. M., Somers, V. K., Le Roux, C. W., Hunter, D. J., Wu, Q., Lalonde, A., Ahmad, N., & Bethel, M. A. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70209 · Cited by 34
“15 We therefore aim to evaluate its potential to reduce body weight and treat complications in individuals with obesity, with or without OSA, OA, T2D, or CVD in the TRIUMPH phase 3 core regulatory registration studies.”
Self-citationNew drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
“Metabolic dysfunction-associated steatohepatitis (MASH) is an attractive target for the medications under development, and two investigational unimolecular agents incorporate glucagon receptor agonism; survodutide [16], a dual GLP-1/GCG RA, and retatrutide [17], a triple GLP-1/GIP/GCG RA.”
Karakasis, P., Vlachos, K. G., Antoniadis, A. P., Siontis, K. C., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156463 · Cited by 56
Kokkorakis, M., Katsarou, A., Katsiki, N., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155689 · Cited by 34
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“Retatrutide represents the current efficacy frontier, demonstrating up to 24.2% weight reduction in the 12 mg group at 48 weeks, approaching bariatric surgery levels without invasive intervention [72,79,80].”
InfluentialGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
“creased [19].”
BackgroundMethodInfluentialNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Yang, Z., Chen, F., Zhang, Y., Ou, M., Tan, P., Xu, X., Li, Q., & Zhou, S. (2024) · MedComm · doi:10.1002/mco2.560 · Cited by 51
“34 In this review, we summarize the changes in WAT in obesity and obesity-related metabolic dysfunction at multiple levels, including cellular changes and underlying regulatory mechanisms.”
BackgroundMechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Grunstein, R. R., Wadden, T. A., Chapman, J. L., Malhotra, A., & Phillips, C. L. (2023) · SLEEP · doi:10.1093/sleep/zsad224 · Cited by 36
A revolution in obesity treatment
Lingvay, I., & Agarwal, S. (2023) · Nature Medicine · doi:10.1038/s41591-023-02538-7 · Cited by 37
Type 2 Diabetes and the Multifaceted Gut-X Axes
Guo, H., Pan, L.-T., Wu, Q., Wang, L., Huang, Z., Wang, J., Wang, L., Fang, X., Dong, S., Zhu, Y., et al. (2025) · Nutrients · doi:10.3390/nu17162708 · Cited by 44
Self-citationGLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies
Yang, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196758 · Cited by 46
“A Phase 2 trial conducted on obese patients showed that retatrutide produced weight loss of 24.2% after 48 weeks, a result that approaches outcomes seen with bariatric surgery [55].”
InfluentialOligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Abbott, S., Adams, B., Agrawal, S., Ahmed, A., Momani, H. A., Al‐Khyatt, W., Al‐Taan, O., Andrews, R. C., Antognozzi, M., Awad, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00025-7 · Cited by 52
“Complications related to technical aspects of surgery included internal hernia repairs after Roux-en-Y gastric bypass (in 15 [4”
The cardiovascular effects of novel weight loss therapies
Usman, M., Davies, M. J., Hall, M. E., Verma, S., Anker, S. D., Rosenstock, J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad664 · Cited by 31
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Chu, J., Zhang, H., Wu, Y. F., Huang, Y., Zhu, T., Zhou, Z., & Wang, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103464 · Cited by 45
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“…or GLP-1/GIP/glucagon triple agonists retatrutide have been extensively investigated in patients with obesity, type 2 diabetes, or cardiovascular disease but recently gained greater attention for other metabolic diseases including MASLD and MASH (NCT05751720; SYNERGY-NASH, NCT04166773) [66–70].”
Bremmer, M. P., & Hendershot, C. S. (2023) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.23-00318 · Cited by 31
Naeem, M., Imran, L., & Banatwala, U. E. S. S. (2024) · Health Science Reports · doi:10.1002/hsr2.1864 · Cited by 30
“In a randomized, double ‐ blind, and placebo ‐ controlled phase 2 study conducted in the United States, 12 in the 4 ‐ mg group (commenced with 4 mg), − 16.7% in the 8 ‐ mg group (started with 2 mg), − 17.9% in the 8 ‐ mg group (initiated with 4 mg), and − 17.5% in the 12 ‐ mg group (commenced with 2 mg), in contrast t…”
BackgroundInfluentialArvanitakis, K., Koufakis, T., Kalopitas, G., Papadakos, S. P., Kotsa, K., & Germanidis, G. S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102935 · Cited by 35
Alkhouri, N., Charlton, M., Gray, M. E., & Noureddin, M. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2473062 · Cited by 34
“%) over 48 weeks [177].”
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
“As a next step, once-weekly subcutaneous retatrutide, a triple GLP-1/GIP/GCGR agonist, led to a dose-dependent up to 24% weight reduction in obese individuals 259 but was only equally effective as dulaglutide regarding glucose lowering.”
BackgroundGLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
A review on tumor-targeting liposomes: Fabrication, mechanism and applications
Basak, S., Das, T. K., & Ganguly, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117460 · Cited by 37
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
“18 Retatrutide also improved liver health, as indicated by reductions in plasma ALT and hepatic triglycerides in obese mice.”
BackgroundStructural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W. (2024) · Cell Discovery · doi:10.1038/s41421-024-00700-0 · Cited by 32
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“In a phase II double-blind, randomized, placebo-controlled trial, Jastreboff et al. administered retatrutide in doses up to 8 mg for a total of 48 weeks in patients with a BMI ≥ 30 kg/m 2 or with a BMI of 27–30 kg/m 2 and a coexisting weight-related condition [39].”
Obesity: a 100 year perspective
Bray, G. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01530-6 · Cited by 44
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2025) · Peptides · doi:10.1016/j.peptides.2025.171380 · Cited by 41
“The once weekly GIPR/GLP-1R/GCGR triple agonist retatrutide has shown marked glucose-lowering and weight-lowering potency in phase 2 trials to treat T2DM and obesity and is effective in MASLD [85,138,139].”
Nutritional Challenges and Treatment After Bariatric Surgery
Moize, V. L., Laferrère, B., & Shapses, S. A. (2024) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061121-101547 · Cited by 40
Sridhar, V. S., Limonte, C. P., Groop, P., Heerspink, H. J. L., Pratley, R. E., Rossing, P. R., Skyler, J. S., & Cherney, D. Z. I. (2023) · Diabetologia · doi:10.1007/s00125-023-06015-1 · Cited by 34
Jiang, Y., Zhu, H., & Gong, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16106 · Cited by 36
“11,12 Comparing results from clinical trials 11,12,31 and animal studies, 99,103 GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist exhibited superior effects on weight reduction and metabolic improvement than GLP-1 mono agonist.”
On the causes of obesity and its treatment: The end of the beginning
Friedman, J. M. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.01.026 · Cited by 34
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
El-Solh, A., Gould, E., Aibangbee, K. E., Jimerson, T., & Hartling, R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2437525 · Cited by 34
“In a phase II multi-center, double-blind, randomized controlled trial, 338 adults with obesity were administered retatrutide (1, 4, 8, and 12 mg) over 48 weeks [106].”
Jarade, C., Zolotarova, T., Moiz, A., & Eisenberg, M. J. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102789 · Cited by 32
“53 Retatrutide treatment also resulted in dose-dependent discontinuation of at least one antihypertensive medication, up to 41% in the retatrutide 8.0 mg arm.”
BackgroundInfluentialThe power of three: Retatrutide’s role in modern obesity and diabetes therapy
Abdul-Rahman, T., Roy, P., Ahmed, F. K., Mueller-Gomez, J. L., Sarkar, S., Garg, N., Femi-Lawal, V. O., Wireko, A. A., Thaalibi, H. I., Hashmi, M. U., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177095 · Cited by 27
Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024) · Obesity Reviews · doi:10.1111/obr.13663 · Cited by 27
Non-canonical G protein signaling
Nürnberg, B., Beer‐Hammer, S., Reisinger, E., & Leiss, V. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108589 · Cited by 30
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Kuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 29
Cross-Talk of NADPH Oxidases and Inflammation in Obesity
Morawietz, H., Brendel, H., Diaba‐Nuhoho, P., Catar, R. A., Perakakis, N., Wolfrum, C., & Bornstein, S. R. (2023) · Antioxidants · doi:10.3390/antiox12081589 · Cited by 30
Moiz, A., Zolotarova, T., Filion, K. B., & Eisenberg, M. J. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpaf205 · Cited by 26
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
Wang, Y., Zhou, J., Yang, Q., Li, X., Qiu, Y., Zhang, Y., Liu, M., & Zhu, A. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100635 · Cited by 35
Marassi, M., Cignarella, A., Russo, G. T., Nollino, L., Strazzabosco, M., Marzullo, P., Leonetti, F., Avogaro, A., Consoli, A., & Fadini, G. P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107866 · Cited by 38
Yin, Y., Zhang, M., Cao, Q., Lin, L., Lu, J., Bi, Y., & Chen, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70082 · Cited by 35
“The therapeutic effects of GLP-1 or GIP- GLP-1 agonists may be enhanced by simultaneously activating the GCG receptor [42], thereby improving the regulation of body fat and energy homeostasis.”
Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
Chen, J., Cooper, M., & Coughlan, M. T. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101641 · Cited by 35
Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon
Roth, C. L., & Zenno, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1256514 · Cited by 29
Henney, A. E., Gillespie, C. S., LAI, J., Schofield, P. G., Riley, D. R. J., Caleyachetty, R., Barber, T. M., Miras, A. D., Dobbie, L. J., Hughes, D. M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae481 · Cited by 36
“Novel incretin-based therapy, such as mono, dual, and triple receptor agonists, may have merit in reducing the burden of steatotic liver disease ( 35), specifically those agents incorporating glucagon agonism, such as retatrutide, due to the direct hepatic activity of glucagon ( 36).”
Rethinking weight loss treatments as cardiovascular medicine in obesity, a comprehensive review
Tuccinardi, D., Watanabe, M., Masi, D., Monte, L., Meffe, L. B., Cavallari, I., Nusca, A., Maddaloni, E., Gnessi, L., Napoli, N., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae171 · Cited by 32
Upadhya, B., Brubaker, P. H., Nicklas, B. J., Houston, D. K., Haykowsky, M. J., & Kitzman, D. W. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.06.007 · Cited by 26
Buckeridge, C., Cobain, S., Bays, H. E., Matsuoka, O., Fukushima, Y., Halstead, P., Tsamandouras, N., Sherry, N., Gorman, D. N., & Saxena, A. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16534 · Cited by 38
Abdrabou Abouelmagd, A., Abdelrehim, A. M., Bashir, M. N., Abdelsalam, F., Marey, A., Tanas, Y., Abuklish, D. M., & Belal, M. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2456441 · Cited by 25
“25 This combination might increase impacts on substrate utilization, energy intake, and energy expenditure.”
InfluentialGlucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions
Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 34
Newer pharmacological interventions directed at gut hormones for obesity
Camilleri, M., & Acosta, A. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16278 · Cited by 29
The role of bone in energy metabolism: A focus on osteocalcin
Smith, C., Lin, X., Parker, L., Yeap, B. B., Hayes, A., & Levinger, I. (2024) · Bone · doi:10.1016/j.bone.2024.117238 · Cited by 36
Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care · doi:10.2337/dc24-2425 · Cited by 25
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“…whether phase 3 clinical trials replicate or even surpass this enhanced efficacy, phase 2 trial data of retatrutide, a GIPR/glucagon-R/GLP-1R triagonist version developed by Eli Lilly and Co, have already shown 24% weight loss after 48 weeks of treatment, without reaching a plateau ( 155 , 156 ).”
BackgroundCVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Barnard-Kelly, K. D., Battelino, T., Ceriello, A., Larsson, H. E., Fernández‐Fernández, B., Forst, T. M., Frías, J. P., Gavin, J. R., Giorgino, F., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02180-8 · Cited by 29
“In the year 2023, the results of two Phase II clinical trials with the triple agonist retatrutide in T2D [102] and obesity [103] were published.”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.